[go: up one dir, main page]

MX2010003620A - Linea de celulas cho-k1. - Google Patents

Linea de celulas cho-k1.

Info

Publication number
MX2010003620A
MX2010003620A MX2010003620A MX2010003620A MX2010003620A MX 2010003620 A MX2010003620 A MX 2010003620A MX 2010003620 A MX2010003620 A MX 2010003620A MX 2010003620 A MX2010003620 A MX 2010003620A MX 2010003620 A MX2010003620 A MX 2010003620A
Authority
MX
Mexico
Prior art keywords
cho
cell
cell line
deposited
atcc ccl
Prior art date
Application number
MX2010003620A
Other languages
English (en)
Inventor
Erhard Kopetzki
Ursula Schwarz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39204855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003620(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010003620A publication Critical patent/MX2010003620A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invenci?n se relaciona con c?lulas CHO-Kl, caracterizada porque la c?lula CHO-Kl se deriva de c?lula CHO-Kl depositada como ATCC CCL-61, crece en suspensi?n, no requiere glutamina, insulina ni factores de crecimiento en el medio de cultivo para crecer, por lo que las c?lulas CHO-Kl no est?n modificadas en comparaci?n con la c?lula CHO-K1 depositada de la l?nea celular ATCC CCL-61 por la introducci?n, supresi?n o inactivaci?n de un ?cido nucleico. Tambi?n se report? un m?todo para obtener la c?lula CHO-Kl y un m?todo para la producci?n de un polip?ptido heter?logo utilizando la c?lula CHO-Kl, de acuerdo con la invenci?n.
MX2010003620A 2007-10-12 2008-10-13 Linea de celulas cho-k1. MX2010003620A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07019999 2007-10-12
PCT/EP2008/008636 WO2009047007A1 (en) 2007-10-12 2008-10-13 Cho-k1 cell line

Publications (1)

Publication Number Publication Date
MX2010003620A true MX2010003620A (es) 2010-04-14

Family

ID=39204855

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013003820A MX338036B (es) 2007-10-12 2008-10-09 Expresion proteinica a partir de acidos nucleicos multiples.
MX2010003622A MX2010003622A (es) 2007-10-12 2008-10-09 Expresion proteinica a partir de acidos nucleicos multiples.
MX2010003620A MX2010003620A (es) 2007-10-12 2008-10-13 Linea de celulas cho-k1.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2013003820A MX338036B (es) 2007-10-12 2008-10-09 Expresion proteinica a partir de acidos nucleicos multiples.
MX2010003622A MX2010003622A (es) 2007-10-12 2008-10-09 Expresion proteinica a partir de acidos nucleicos multiples.

Country Status (20)

Country Link
US (5) US8771988B2 (es)
EP (4) EP2207881A1 (es)
JP (2) JP5642549B2 (es)
KR (2) KR101280704B1 (es)
CN (2) CN101815786A (es)
AU (2) AU2008309934B2 (es)
BR (2) BRPI0818165B8 (es)
CA (2) CA2701646C (es)
DK (1) DK2592148T3 (es)
ES (1) ES2695999T3 (es)
HR (1) HRP20181833T1 (es)
HU (1) HUE039950T2 (es)
IL (2) IL203902A0 (es)
LT (1) LT2592148T (es)
MX (3) MX338036B (es)
PL (1) PL2592148T3 (es)
PT (1) PT2592148T (es)
SI (1) SI2592148T1 (es)
TR (1) TR201816045T4 (es)
WO (2) WO2009046978A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803484A (zh) * 2009-06-11 2012-11-28 大学共同利用机关法人情报·系统研究机构 生产蛋白质的方法
ES2948572T3 (es) 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
AU2010317609A1 (en) * 2009-11-16 2012-07-05 Acyte Biotech Pty Ltd Recombinant antibody vector
WO2011065940A1 (en) * 2009-11-24 2011-06-03 Biogen Idec Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
US8986957B2 (en) 2010-04-26 2015-03-24 Novartis Ag Cell culture medium
EP2616541B1 (en) 2010-09-15 2014-11-12 MedImmune Limited Chinese hamster ovary cell line
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
EP2773671B1 (en) 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
BR112014012667A2 (pt) 2011-12-22 2018-10-09 F Hoffmann-La Roche Ag vetor de expressão, usos de vetor de expressão, método de transfecção de células eucarióticas, uso de método, uso de célula, métodos de produção de anticorpos e método de transfecção
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EP2674495A1 (en) * 2012-06-14 2013-12-18 Sanofi CHO expression system
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
BR112015021993A8 (pt) 2013-03-15 2019-12-03 Genentech Inc polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
PL3074424T3 (pl) 2013-11-27 2025-06-09 Zymeworks Bc Inc. Bispecyficzne konstrukty wiążące antygen ukierunkowane na her2
US11124760B2 (en) 2014-03-24 2021-09-21 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
KR20230164192A (ko) 2014-05-06 2023-12-01 제넨테크, 인크. 포유동물 세포를 사용한 이종다량체 단백질의 생산
CN107075475B (zh) * 2014-07-16 2021-04-27 心脏康复株式会社 新型去除未分化干细胞和纯化精制心肌细胞的培养基
EP3693469A1 (en) * 2015-04-27 2020-08-12 Momenta Pharmaceuticals, Inc. Method of manufacturing a therapeutic protein
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
GB201718088D0 (en) * 2017-11-01 2017-12-13 Autolus Ltd Vectors
CN111019881B (zh) * 2019-11-21 2020-10-09 中山康天晟合生物技术有限公司 一种适应高渗透压、高铵离子、高乳酸生长环境的细胞
US20230265204A1 (en) 2020-04-24 2023-08-24 Hoffmann-La Roche Inc. Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN112920995A (zh) * 2021-03-31 2021-06-08 赵峻岭 一种间充质干细胞培养血清加油包及其应用
CN115521919B (zh) * 2022-11-04 2023-04-11 广州誉衡生物科技有限公司 一种调节pd-1抗体和lag-3抗体酸性电荷异构体的cho细胞培养方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912038A (en) 1984-12-11 1990-03-27 California Biotechnology Inc. Recombinant DNA sequence encoding alveolar surfactant protein
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
AU2263288A (en) 1987-07-16 1989-02-13 Codon Transfected cells containing plasmids having genes oriented in opposing directions and methods of obtaining the same
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
EP0319206A3 (en) 1987-11-30 1990-04-18 Berlex Laboratories, Inc. Gene amplification
WO1989010959A1 (en) 1988-05-06 1989-11-16 Codon Supertransformants for high expression rates in eukaryotic cells
DD287531A5 (de) 1988-06-16 1991-02-28 Akademie Der Wissenschaften,De Verfahren zur herstellung von humanem wachstumshormon (sth) in tierischen zellen
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
JP2859679B2 (ja) * 1990-03-01 1999-02-17 協和醗酵工業株式会社 新規細胞株
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
GB9114468D0 (en) * 1991-07-04 1991-08-21 Wellcome Found Antibody production
EP0569678A3 (de) 1992-03-13 1994-10-26 Yeda Res & Dev Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
WO1994025067A1 (en) 1993-05-04 1994-11-10 Cytel Corporation Antibodies to p-selectin and their uses
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
AU7568094A (en) 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
WO1995017513A1 (en) * 1993-12-23 1995-06-29 Novo Nordisk A/S Retransformation of filamentous fungi
US5719050A (en) * 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
WO1997008342A1 (en) 1995-08-30 1997-03-06 Gentest Corporation Cytochrome p450 reporter gene
EP0953041A4 (en) 1996-08-30 2003-01-29 Life Technologies Inc SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
AU5874798A (en) 1997-01-31 1998-08-25 Biovation Limited Vaccination methods and molecules
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
CA2310987A1 (en) 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
IL138523A0 (en) * 1998-03-18 2001-10-31 Pharmacopeia Inc Eukaryotic cells stably expressing genes from multiple transfected episomes
BR9905867A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
TW570977B (en) 1998-12-07 2004-01-11 Li-Wei Hsu An expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
DE19920712A1 (de) 1999-05-05 2000-11-09 Rhein Biotech Proz & Prod Gmbh Verfahren zum Herstellen eines rekombinanten Proteines
NZ517215A (en) * 1999-08-25 2004-01-30 Immunex Corp Compositions and methods for improved cell culture
AUPQ422399A0 (en) 1999-11-24 1999-12-16 University Of New South Wales, The Method of screening transformed or transfected cells
DE10036491A1 (de) * 2000-07-25 2002-02-07 Roche Diagnostics Gmbh Expression von Alkalischer Phosphatase in Hefe
US20050084969A1 (en) 2001-11-28 2005-04-21 Kurt Schorgendorfer Method for producing a recombinant polypeptide
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2003076588A2 (en) 2002-03-05 2003-09-18 Vitra Bioscience, Inc. Multiplexed cell transfection using coded carriers
DE10213201A1 (de) 2002-03-25 2003-10-16 Roche Diagnostics Gmbh Erzeugung von schwach aktiven oder inaktiven Mutanten von Alkalischer Phosphatase und deren Expression in Hefe
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2004087758A2 (en) 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
WO2005113770A1 (en) 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
DE102005046225B4 (de) * 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
TW200722436A (en) 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
BRPI0708902A2 (pt) * 2006-03-16 2011-06-14 Genentech Inc mÉtodos de tratar lupus usando anticorpos cd4
CA2647808C (en) * 2006-03-30 2015-11-17 Glaxo Group Limited Antibodies against amyloid-beta peptide
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos

Also Published As

Publication number Publication date
US20170166923A1 (en) 2017-06-15
TR201816045T4 (tr) 2018-11-21
CN101815786A (zh) 2010-08-25
PL2592148T3 (pl) 2019-01-31
CA2701677A1 (en) 2009-04-16
US20100249379A1 (en) 2010-09-30
WO2009047007A1 (en) 2009-04-16
MX2010003622A (es) 2010-04-14
IL203902A0 (en) 2011-07-31
EP2592147A1 (en) 2013-05-15
LT2592148T (lt) 2018-12-10
BRPI0818165B1 (pt) 2020-10-27
HUE039950T2 (hu) 2019-02-28
AU2008309881A1 (en) 2009-04-16
ES2695999T3 (es) 2019-01-11
US20100221781A1 (en) 2010-09-02
EP2207882A1 (en) 2010-07-21
US20140335609A1 (en) 2014-11-13
AU2008309934A1 (en) 2009-04-16
CA2701646C (en) 2019-02-26
AU2008309934B2 (en) 2014-03-06
SI2592148T1 (sl) 2018-12-31
US8771988B2 (en) 2014-07-08
EP2592148B1 (en) 2018-09-12
US9428766B2 (en) 2016-08-30
CN101821394A (zh) 2010-09-01
BRPI0818165B8 (pt) 2021-05-25
CA2701646A1 (en) 2009-04-16
JP2011500009A (ja) 2011-01-06
KR20100059969A (ko) 2010-06-04
KR101280704B1 (ko) 2013-07-01
DK2592148T3 (en) 2018-12-10
EP2592148A1 (en) 2013-05-15
BRPI0818165A2 (pt) 2014-10-14
WO2009046978A1 (en) 2009-04-16
US20190233842A1 (en) 2019-08-01
JP5642549B2 (ja) 2014-12-17
JP2010540583A (ja) 2010-12-24
KR20100059967A (ko) 2010-06-04
IL203900A0 (en) 2011-07-31
EP2207881A1 (en) 2010-07-21
BRPI0818536A2 (pt) 2014-10-14
HRP20181833T1 (hr) 2019-01-11
PT2592148T (pt) 2018-11-12
MX338036B (es) 2016-03-31
IL203900A (en) 2014-08-31

Similar Documents

Publication Publication Date Title
MX2010003620A (es) Linea de celulas cho-k1.
MX2016010236A (es) Modulacion del crecimiento celular y glucosilacion en la produccion de glucoproteina recombinante.
WO2011112781A3 (en) Enterobacter sp. 638 and methods of use thereof
CA2801799C (en) Filamentous fungal host strains and dna constructs, and methods of use thereof
WO2021097452A3 (en) Biosynthetic production of psilocybin and related intermediates in recombinant organisms
MX2011011491A (es) Manipulacion de la biosintesis de fructosano y aumento de biomasa vegetal.
WO2011091350A3 (en) Methods & compositions for improving protein production
NZ703137A (en) Cells for producing recombinant iduronate-2-sulfatase
EP3626051A3 (en) Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
WO2012056109A3 (en) Plant derived cell culture material
EP4446338A3 (en) Cells and method of cell culture
NZ586250A (en) Cell culture processes
SG158025A1 (en) Growth medium c. histolyticum without ingredients of mamalian sources
PL2144929T3 (pl) Poprawa mian polipeptydu czynnika VIII w hodowlach komórkowych
MX2009008175A (es) Metodos para producir vacunas basadas en levadura.
WO2011134919A3 (en) Cho cells cultivation process 0
WO2010006312A3 (en) Methods and compositions for producing carbon-based products in microorganisms
MY154509A (en) Re-engineering bacteria for ethanol production
WO2019177371A8 (ko) 미생물을 이용한 폴리(3-하이드록시프로피오네이트-b-락테이트) 블록공중합체
MX2018012297A (es) Metodo para la produccion de acido lactico.
WO2010027233A2 (ko) Thermococcus supp.로부터 분리된 신규한 수소화효소, 이를 암호화하는 유전자 및 그 유전자를 갖는 미생물을 이용하여 수소를 생산하는 방법
WO2011115439A3 (ko) 5'-크산틸산 및 5'-구아닐산 생산능이 향상된 미생물 및 이를 이용한 5'-크산틸산 또는 5'-구아닐산의 생산방법
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.
UA106047C2 (uk) Спосіб отримання високої щільності життєздатних клітин в культурі клітин ссавців
MY188792A (en) Process for producing biomass using a geseous substrate comprising co2 and methane

Legal Events

Date Code Title Description
FA Abandonment or withdrawal